

**Performance of the EULAR Systemic sclerosis Impact of Disease (SclerIOD) questionnaire as a patient reported outcome measure for patients with diffuse systemic sclerosis**

Rucsandra Dobrota<sup>1</sup>, Alexandru Garaiman<sup>1</sup>, Kim Fligelstone<sup>2</sup>, Ann Tyrell Kennedy<sup>2</sup>, Annelise Roennow<sup>2</sup>, Yannick Allanore<sup>3</sup>, Patricia E. Carreira<sup>4</sup>, László Czirják<sup>5</sup>, Christopher P. Denton<sup>6</sup>, Roger Hesselstrand<sup>7</sup>, Gunnel Sandqvist<sup>7</sup>, Otylia Kowal-Bielecka<sup>8</sup>, Cosimo Bruni<sup>1,9</sup>, Marco Matucci-Cerinic<sup>9</sup>, Carina Mihai<sup>1,10</sup>, Ana Maria Gheorghiu<sup>10</sup>, Ulf Müller-Ladner<sup>11</sup>, Tore K Kvien<sup>12,13</sup>, Turid Heiberg<sup>14</sup>, Oliver Distler<sup>1</sup>, Mike O. Becker<sup>1</sup>

1. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
2. Federation of European Scleroderma Associations (FESCA)
3. Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France
4. Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain
5. Department of Immunology and Rheumatology, Medical School, University of Pécs, Pécs, Hungary
6. Centre for Rheumatology, University College London, Royal Free Campus, London, United Kingdom
7. Department of Rheumatology, Lund University, Lund, Sweden
8. Department of Rheumatology and Internal Medicine, Medical University of Białystok, Białystok, Poland
9. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
10. Department of Internal Medicine and Rheumatology, Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
11. Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Campus Kerckhoff, Bad Nauheim, Bad Nauheim, Germany
12. Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
13. Faculty of Medicine, University of Oslo, Oslo, Norway
14. Regional Research Support, Oslo University Hospital, Oslo, Norway

**Corresponding author:**

Mike Becker, MD

Department of Rheumatology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich

E-Mail: [MikeOliver.Becker@usz.ch](mailto:MikeOliver.Becker@usz.ch)

Phone +41 44 255 29 70; Fax: +41 44 255 89 79

## Supplementary methods

### Sensitivity to change

**Patients answered the following Likert scale question to assess their overall disease status at 12 months' follow-up:**


S4. Think about all the ways your systemic sclerosis has affected you during the last week.

**Compared to 6 months ago, how has the overall state of your disease been during the last week? (Mark "X" in only one box below)<sup>1</sup>**


- Much improved
- Moderately improved
- Stable (mostly unchanged)
- Moderately worsened
- Much worsened

## Supplementary results


**Figure S1.** Distribution of missing data among the SclerID items.



**Figure S2.** Distribution of the SclerID global scores of the dcSSc patients without a relevant a ceiling/floor effect.



**Figure S3.** Distribution of the individual SclerolD scores per item in the whole dcSSc patient cohort.



**Table S1.** Construct validity analysis by correlation between ScleroID and other established PROMs, point estimations with precision.

PROMs	Spearman's correlation coefficients, estimation and precision 95%
ScleroID & SF-36 (PCS)	-0.69 [-0.77 to -0.57]
ScleroID & SF-36 (MCS)	-0.51 [-0.63 to -0.36]
ScleroID & HAQ	0.72 [0.6 to 0.8]
ScleroID & SHAQ	0.79 [0.69 to 0.86]
ScleroID & EQ-5D	-0.65 [-0.75 to -0.52]
SF-36: Short Form-36 Health Survey, PCS: physical component summary, MCS: mental component summary, HAQ: health assessment questionnaire, SHAQ: scleroderma health assessment questionnaire, EQ-5D: standardised measure of health-related quality of life developed by the EuroQol Group (based on 5 questions)	

#### Supplementary References

1. Becker MO, Dobrota R, Garaiman A, Debelak R, Fligelstone K, Tyrrell Kennedy A, et al. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire. *Ann Rheum Dis*. 2022;81(4):507-15.